Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Recruiting

Phase 2

FRαDCsFolate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Sponsor:

Mayo Clinic

Code:

NCT06639074

Conditions

Advanced Fallopian Tube Carcinoma

Advanced Fallopian Tube High Grade Serous Adenocarcinoma

Advanced Ovarian Carcinoma

Advanced Ovarian Carcinosarcoma

Advanced Ovarian Clear Cell Adenocarcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Computed Tomography

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

Leukapheresis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-25. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2025-03-06.